Nanobiotechnology for the prevention of dialysis-related amyloidosis

Therapeutic Apheresis and Dialysis

Volumn 13, Issue 1, 2009, Pages 34-41

  Stamopoulos, Dimosthenis ^a,e   Bouziotis, Penelope ^a   Benaki, Dimitra ^a   Zirogiannis, Panagiotis N ^b   Kotsovassilis, Kostantinos ^b   Belessi, Vassiliki ^a   Dalamagas, Vassilis ^c   Papadopoulos, Kostantinos ^d  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d Dialysis Center Filoxenia   (Greece)

^e INSTITUTE OF MATERIALS SCIENCE   (Greece)

Author keywords

2 microglobulin; Dialysis related amyloidosis; Hemodialysis; Magnetically assisted hemodialysis

Indexed keywords

BETA 2 MICROGLOBULIN; BOVINE SERUM ALBUMIN; FERROMAGNETIC MATERIAL; NANOPARTICLE;

AMYLOIDOSIS; ARTICLE; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; DIALYSIS AMYLOIDOSIS; HEMODIALYSIS; IN VITRO STUDY; MAGNETICALLY ASSISTED HEMODIALYSIS; MAGNETISM; NANOBIOTECHNOLOGY; PRIORITY JOURNAL;

ADSORPTION; AMYLOIDOSIS; ANIMALS; BETA 2-MICROGLOBULIN; CATTLE; FERROSOFERRIC OXIDE; MAGNETICS; NANOPARTICLES; NANOTECHNOLOGY; RENAL DIALYSIS; SERUM ALBUMIN, BOVINE; SEVERITY OF ILLNESS INDEX;

EID: 62149134832     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00603.x     Document Type: Article

References (31)

1. Vanholder R, Argilés A, Baurmeister U et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001 24 : 695 725.
2. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003 63 : 1934 43.
3. Vanholder R, De Smet R, Glorieux G, Dhondt A. Survival of hemodialysis patients and uremic toxin removal. Artif Organs 2003 27 : 218 23.
4. Suliman M, Stenvinkel P, Qureshi AR et al. The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant 2007 22 : 209 17.
5. Refsum H, Smith AD, Ueland PM et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004 50 : 3 32.
6. Suliman ME, Bárány P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia - a puzzling and conflicting story. Nephrol Dial Transplant 2005 20 : 16 21.
7. Pizzolo F, Friso S, Olivieri O et al. Homocysteine, traditional risk factors and impaired renal function in coronary artery disease. Eur J Clin Invest 2006 36 : 698 704.
8. Ducloux D, Klein A, Kazory A. Impact of malnutrition inflammation on the association between homocysteine and mortality. Kidney Int 2006 69 : 331 5.
9. 2- microglobulin. Biochem Biophys Res Commun 1985 129 : 701 6.
10. Gorevic PD, Casey TT, Stone WJ. Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest 1985 76 : 2425 9.
11. Drüeke TB. Dialysis-related amyloidosis. Nephrol Dial Transplant 1998 13 : 58 64.
12. Ronco C, Nissenson AR. Does nanotechnology apply to dialysis? Blood Purif 2001 19 : 347 52.
13. Bowry SK. Nano-controlled membrane spinning technology: regulation of pore size, distribution and morphology of a new polysulfone dialysis membrane. Contrib Nephrol 2002 137 : 85 94.
14. Humes HD, Fissell WH, Tiranathanagul K. The future of hemodialysis membranes. Kidney Int 2006 69 : 1115 9.
15. Fissell WH, Humes HD, Fleischman AJ, Roy S. Dialysis and nanotechnology: now, 10 years, or never? Blood Purif 2007 25 : 12 7.
16. Nissenson AR, Ronco C, Pergamit G, Edelstein M, Watts R. The human nephron filter: toward a continuously functioning, implantable artificial nephron system. Blood Purif 2005 23 : 269 74.
17. Nissenson AR, Ronco C, Pergamit G, Edelstein M, Watts R. Continuously functioning artificial nephron system: the promise of nanotechnology. Hemodial Int 2005 9 : 210 7.
18. Stamopoulos D, Benaki D, Bouziotis P, Zirogiannis PN. In vitro utilization of ferromagnetic nanoparticles in hemodialysis therapy. Nanotechnology 2007 18 : 495102.
19. Stamopoulos D, Bouziotis P, Benaki D, Kotsovassilis C, Zirogiannis PN. Utilization of nanobiotechnology in haemodialysis: mock-dialysis experiments on homocysteine. Nephrol Dial Transplant 2008 23 : 3234.
20. 4 ferromagnetic nanoparticles for utilization in magnetically assisted hemodialysis: biocompatibility with human blood cells. Nanotechnology 2008 19 : 505101.
21. Giacomelli CE, Norde W. The adsorption-desorption cycle. reversibility of the BSA-silica system. J Colloid Interface Sci 2001 233 : 234 40.
22. Danielson BG. Structure chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004 15 : S93 8.
23. National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. New York : National Kidney Foundation, 2000.
24. Gejyo F, Odani S, Yamada T. β2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 1986 30 : 385 90.
25. Gorevic PD, Casey TT, Stone WJ, Diraimondo CR, Prelli FC, Frangione B. Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest 1985 76 : 2425 9.
26. Saito A, Gejyo F. Current clinical aspects of dialysis-related amyloidosis in chronic dialysis patients. Ther Apher Dial 2006 10 : 316 20.
27. Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The working party on dialysis amyloidosis. Kidney Int 1991 39 : 1012 19.
28. Aoike I, Gejyo F, Arakawa M. Learning from the Japanese Registry: how will we prevent long-term complications? Niigata Research Programme for beta2-M Removal Membrane. Nephrol Dial Transplant 1995 10 : 7 15.
29. Koda Y, Nishi S, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997 52 : 1096 101.
30. Fry AC, Singh DK, Chandna SM, Farrington K. Relative importance of residual renal function and convection in determining Bate-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif 2007 25 : 295 302.
31. Saito A, Kazama JJ, Iino N et al. Bioengineered implantation of megalin-expressing cells: a potential intracorporeal therapeutic model for uremic toxin protein clearance in renal failure. J Am Soc Nephrol 2003 14 : 2025 32.